Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.000
+0.080 (2.04%)
At close: Oct 13, 2025, 4:00 PM EDT
4.000
0.00 (0.00%)
After-hours: Oct 13, 2025, 5:56 PM EDT
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
Country | United States |
Founded | 1997 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 59 |
CEO | Vipin Garg |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
Phone | 240 654 1450 |
Website | altimmune.com |
Stock Details
Ticker Symbol | ALT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001326190 |
CUSIP Number | 02155H200 |
ISIN Number | US02155H2004 |
Employer ID | 20-2726770 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer and Director |
Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 3, 2025 | 8-K | Current Report |
Sep 25, 2025 | 8-K | Current Report |
Aug 19, 2025 | UPLOAD | Filing |
Aug 15, 2025 | ARS | Filing |
Aug 15, 2025 | DEF 14A | Other definitive proxy statements |
Aug 12, 2025 | 10-Q | Quarterly Report |
Aug 12, 2025 | 8-K | Current Report |
Aug 8, 2025 | UPLOAD | Filing |
Jul 16, 2025 | SCHEDULE 13G/A | Filing |
Jun 26, 2025 | 8-K | Current Report |